Research Library
Curated Studies & Clinical Data
A growing library of peer-reviewed studies, clinical trial data, and systematic reviews organized by compound. Every citation is linked to its primary source.
Effectiveness & safety of semaglutide in weight reduction in obese nondiabetic patients: A systematic review and meta-analysis
Naz F, Qaiser F, Mumtaz A, et al.
Medicine;105(31):e49986
[An historical overview of GLP-1/GIP incretins. From hormone to “swiss-army knife” medications]
Portha B
Biologie aujourd'hui, 2026;220(1-2):9-24
Hypertensive disorders of pregnancy and GLP-1 receptor agonist timing: a systematic review and meta-analysis
Pisani D, Lorenza D, Fordellone M, et al.
Endocrine, 2026;91(1)
Early changes in renal function do not appear to mediate cardiovascular risk with dapagliflozin plus semaglutide: a real-world observational hypothesis-generating cohort study
AlTaweel MO, Al Makhloof S, AlKhayyal AK, et al.
Expert review of cardiovascular therapy, 2026
Current Updates on Pharmacotherapy for Obstructive Sleep Apnea
Kim SW
Journal of rhinology : official journal of the Korean Rhinologic Society, 2026;33(2):87-94
Glucagon-like peptide-1 and peptide YY multi-agonism with GEP44 to optimize weight loss and glycemic control while reducing gastrointestinal side effects: the future of anti-obesity pharmacotherapy?
Burmeister MA, Brown SA, Greer JJ, et al.
Frontiers in endocrinology, 2026;17:1925534
Retatrutide effects on diabetic rats’ cognition
Ferreira J
Lab animal;55(8):287
Abrupt Smoking Cessation Due to Sensory Aversion Following Tirzepatide Initiation
Ceesay OI, Rokusek B, Rasmussen J, et al.
The primary care companion for CNS disorders, 2026;28(4)
Design of a metabolically-stable peptide therapeutic with triple-hormone-receptor agonist activity
Vishnoi S, Hudson S, Bhattacharya S, et al.
Journal of computer-aided molecular design, 2026;40(1)
Effect of Medications for Type 2 Diabetes on Cardiovascular Events and Mortality: A Comprehensive Pairwise and Network Meta-Analysis
Silverii GA, Velardi V, Marinelli C, et al.
Diabetes, obesity & metabolism, 2026
Incorporating estimands into meta-analyses of clinical trials
Remiro-Azócar A, Polavieja P, Boutmy E, et al.
Research synthesis methods, 2026;:1-28
Outpatient Dispensing Patterns and Changes in Tirzepatide Strength Mix in Japan: A Study Using the National Open Claims Data
Omura T, Kamihara T
Cureus, 2026;18(7):e113681
Prescription Sequence Symmetry Analysis of Glucagon-Like Peptide-1 Receptor Agonists and Neuropsychiatric Conditions
Alfonso Arvez MJ, Wade S, Goordeen D, et al.
Clinical pharmacology and therapeutics, 2026
Impurities and Potential Immunogenicity Associated With Follow-on and Compounded Glucagon-like Peptide-1 Receptor Agonists
Kopp KL, Lamberth K, Schelde O, et al.
Pharmaceutical research, 2026
Concurrent initiation of tirzepatide and biologics improves patient-reported outcomes in obese psoriatic arthritis: a propensity score-matched study
Venerito V, Lopalco G, Colaprico C, et al.
RMD open, 2026;12(3)
Adipose Tissue Dysfunction in Metabolic Dysfunction-Associated Steatotic Liver Disease
Cruz AJL, Yuan L
Cells, 2026;15(15)
Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, and Atrial Fibrillation: An Umbrella Review With Methodological Appraisal of Overlapping Meta-Analyses
Ramzy D, Isshak R, Patel D, et al.
Cureus, 2026;18(7):e113641
Multisystem Benefits of GLP-1 Microdosing: A Narrative Review
Panlilio MA, Piserchio N, Hennessey M, et al.
Cureus, 2026;18(7):e113635
Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial
Schacht JP, Sakai JT, Raymond K, et al.
The American journal of psychiatry, 2026;:appiajp20260003
PYY3-36 potentiates Semaglutide‑mediated mitochondrial modulation in MASLD
Geiger N, Nickel AG, Kohlhaas M, et al.
American journal of physiology. Endocrinology and metabolism, 2026